Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment